Quick Answer
Amylyx Pharmaceuticals, Inc. reported Research And Development Expense of $90.40 million for the year ending 2025.
- Amylyx Pharmaceuticals, Inc. showed a decrease of -13.1% in Research And Development Expense from 2024 to 2025.
- This data is from Amylyx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $6.86 million | Q2 2021: $10.93 million | Q3 2021: $12.85 million | Q1 2022: $21.46 million | Q2 2022: $24.26 million | Q3 2022: $24.91 million | Q1 2023: $24.19 million | Q2 2023: $29.04 million | Q3 2023: $30.04 million | Q1 2024: $36.61 million | Q2 2024: $23.35 million | Q3 2024: $21.24 million | Q1 2025: $22.12 million | Q2 2025: $27.22 million | Q3 2025: $19.86 million.
- Over the full 5 years of available data (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s Research And Development Expense has grown by 105.3%.
- Historical annual values: Fiscal year 2025: $90.40 million | Fiscal year 2024: $104.08 million | Fiscal year 2023: $128.19 million | Fiscal year 2022: $93.45 million | Fiscal year 2021: $44.04 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: